Register Login

ARS PHARMACEUTICALS, INC. (SPRY)

SymbolSPRY
NameARS PHARMACEUTICALS, INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address500 FAIRVIEW AVENUE N,SUITE 600, SEATTLE, Washington, 98109, United States
Telephone+1 206 456-2900
Fax—
Email—
Websitehttps://www.ars-pharma.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001671858
Description

ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

Additional info from NASDAQ:
ARS Pharmaceuticals Inc is a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis. The company is developing neffy, an intranasal epinephrine product in clinical development for patients and their caregivers with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.

2026-07-16 14:00

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ARS Pharmaceuticals, Inc. - SPRY

Read more
2026-07-07 20:38

(99% Neutral) ARS PHARMACEUTICALS, INC. (SPRY) Announces New Board Appointment

Read more
2026-07-07 20:30

ARS Pharmaceuticals Announces CEO Succession

Read more
2026-07-02 20:30

Casale Donn 🟢 acquired 898.5K shares (1 derivative) of ARS Pharmaceuticals, Inc. (SPRY) at $7.96 ($7.2M) Transaction Date: Jul 01, 2026 | Filing ID: 000007

Read more
2026-07-01 14:07

SPRY Investor Alert: Levi & Korsinsky Investigates ARS Pharmaceuticals (SPRY) for Potential Securities Fraud

Read more
2026-06-28 15:54

SPRY Investors Have Opportunity to Join ARS Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm

Read more
2026-06-26 20:52

RA CAPITAL MANAGEMENT, L.P. 🟢 acquired 30.0K shares (1 derivative) of ARS Pharmaceuticals, Inc. (SPRY) at $10.54 Transaction Date: Jun 24, 2026 | Filing ID: 000704

Read more
2026-06-25 21:01

(99% Neutral) ARS PHARMACEUTICALS, INC. (SPRY) Announces Regulatory Update

Read more
2026-06-24 20:05

ARS Pharmaceuticals Provides Commercial and Financial Updates

Read more
2026-06-13 00:06

Karas Eric 🟡 adjusted position in 25.0K shares (1 derivative) of ARS Pharmaceuticals, Inc. (SPRY) at $10.00 Transaction Date: Jun 12, 2026 | Filing ID: 000004

Read more
Trial ID Title Phase Indication Status Start Date Completion Date Source
NCT06927999 An Outpatient Study of the Efficacy of ARS-2 in Patients With Chronic Spontaneo… Phase2 Urticaria Chronic Recruiting 2025-07-09 2026-06-01 ClinicalTrials.gov
NCT06834165 Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in… Phase4 Allergic Reactions Recruiting 2025-05-20 2027-06-01 ClinicalTrials.gov
NCT05496465 Safety and Efficacy of Intranasal Epinephrine After Administration of ARS -1 in… Phase2 Urticaria Completed 2022-07-28 2024-02-29 ClinicalTrials.gov
NCT05363670 Administration of ARS-1 or Albuterol in Subjects With Persistent Asthma Phase2 Asthma Completed 2022-07-28 2024-02-02 ClinicalTrials.gov
NCT04930900 Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With … Phase1 Upper Respiratory Tract Infection Completed 2021-08-09 2022-07-25 ClinicalTrials.gov
Total clinical trials: 5
Product Name Type Development Stage Therapeutic Area Study Status Trial ID
ARS-1 without URTI Other Phase PHASE1 Upper Respiratory Tract Infection COMPLETED NCT04930900
ARS-1 with URTI Other Phase PHASE1 Upper Respiratory Tract Infection COMPLETED NCT04930900
Placebo Other Phase PHASE2 Asthma COMPLETED NCT05363670
Albuterol MDI Other Phase PHASE2 Asthma COMPLETED NCT05363670
ARS-1 Other Phase PHASE2 Asthma COMPLETED NCT05363670
1 mg epinephrine Other Phase PHASE2 Urticaria Chronic RECRUITING NCT06927999
0.5 mg epinephrine Other Phase PHASE2 Urticaria Chronic RECRUITING NCT06927999
Placebo Other Phase PHASE2 Urticaria Chronic RECRUITING NCT06927999
ARS-1 Other Phase PHASE2 Urticaria COMPLETED NCT05496465
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Adrenaline Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy Other Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
123 I - ALTROPANE® DRUG Phase PHASE3 Parkinsonian Syndromes UNKNOWN NCT00724906
AG-013736 DRUG Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00949624
Docetaxel DRUG Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00949624
CP-868,596 DRUG Phase PHASE1 Advanced Solid Tumors COMPLETED NCT00949624
CP-868,596 + AG-013736 + docetaxel DRUG Phase PHASE2 Carcinoma, Non-Small-Cell Lung WITHDRAWN NCT00386555
AG-013736 + docetaxel DRUG Phase PHASE2 Carcinoma, Non-Small-Cell Lung WITHDRAWN NCT00386555
CP-868,596 + docetaxel DRUG Phase PHASE2 Carcinoma, Non-Small-Cell Lung WITHDRAWN NCT00386555
docetaxel DRUG Phase PHASE2 Carcinoma, Non-Small-Cell Lung WITHDRAWN NCT00386555
Glycerin ear drops DRUG Phase PHASE3 Acute Otitis Media COMPLETED NCT02044341
benzocaine DRUG Phase PHASE2 Pain COMPLETED NCT01588535
Isosorbide dinitrate / hydralazine capsules DRUG Phase PHASE1 Healthy COMPLETED NCT01587313
AR08 DRUG Phase PHASE2 Vasomotor Symptoms (VMS) TERMINATED NCT02049164
acetylcysteine DRUG Phase PHASE1 Healthy COMPLETED NCT02723669
AR10 DRUG Phase PHASE1 Healthy COMPLETED NCT02723669
BiDil Immediate Release (IR) DRUG Phase PHASE1 Heart Failure COMPLETED NCT02522208
BiDil XR DRUG Phase PHASE1 Heart Failure COMPLETED NCT02522208
Placebo Comparator DRUG Phase PHASE3 Acute Otitis Media TERMINATED NCT02074007
AR01 DRUG Phase PHASE3 Acute Otitis Media COMPLETED NCT02044341
methotrexate, hydrocortisone and cytarabine with leucovorin DRUG Phase PHASE1 Acute Myeloid Leukemia COMPLETED NCT02270788
Sorafenib DRUG Phase PHASE1 Acute Myeloid Leukemia COMPLETED NCT02270788
Crenolanib besylate (CP-868,596-26), Dose: 140mg BID DRUG Phase PHASE2 D842-related Mutant GIST COMPLETED NCT01243346
gabapentin enacarbil DRUG Phase PHASE2 Alcohol Use Disorder COMPLETED NCT02252536
Duanorubicin DRUG Phase PHASE3 Newly Diagnosed FLT3 Mutated AML UNKNOWN NCT03258931
Midostaurin DRUG Phase PHASE3 Newly Diagnosed FLT3 Mutated AML UNKNOWN NCT03258931
Paclitaxel DRUG Phase PHASE1 Esophagogastric Adenocarcinoma COMPLETED NCT03193918
Ramucirumab DRUG Phase PHASE1 Esophagogastric Adenocarcinoma COMPLETED NCT03193918
AR11 DRUG Phase PHASE4 Attention Deficit Hyperactivity Disorder (ADHD) COMPLETED NCT01986062
Placebo Oral Tablet DRUG Phase PHASE3 Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations UNKNOWN NCT03250338
placebo DRUG Phase PHASE2 Pain COMPLETED NCT01588535
AR09 solution DRUG Phase PHASE1 Anesthesia TERMINATED NCT02027155
Crenolanib DRUG Phase PHASE1 Diffuse Intrinsic Pontine Glioma COMPLETED NCT01393912
Crenolanib Besylate (CP-868,596-26) DRUG Phase PHASE2 Relapsed or Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations COMPLETED NCT01522469
idarubicin DRUG Phase PHASE2 Newly Diagnosed AML With FLT3 Activating Mutations COMPLETED NCT02283177
daunorubicin DRUG Phase PHASE2 Newly Diagnosed AML With FLT3 Activating Mutations COMPLETED NCT02283177
cytarabine DRUG Phase PHASE2 Newly Diagnosed AML With FLT3 Activating Mutations COMPLETED NCT02283177
crenolanib DRUG Phase PHASE2 Recurrent/Refractory Glioblastoma COMPLETED NCT02626364
G-CSF DRUG Phase PHASE3 Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations UNKNOWN NCT03250338
Fludarabine DRUG Phase PHASE3 Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations UNKNOWN NCT03250338
Etoposide DRUG Phase PHASE1 Relapsed/Refractory Acute Myeloid Leukemia (AML) COMPLETED NCT02626338
Mitoxantrone DRUG Phase PHASE3 Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations UNKNOWN NCT03250338
Azacytidine DRUG Phase PHASE1 Acute Myeloid Leukemia COMPLETED NCT02400281
Cytarabine DRUG Phase PHASE3 Newly Diagnosed FLT3 Mutated AML UNKNOWN NCT03258931
Idarubicin DRUG Phase PHASE3 Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations UNKNOWN NCT03250338
Crenolanib besylate DRUG Phase PHASE2 Acute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior Therapies COMPLETED NCT01657682
GE-IR 450 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06247488
GE-IR 200 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06247488
Oxycodone 20 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06247488
Gabapentin Enacarbil Immediate Release (GE-IR) 700 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06097676
Gabapentin Enacarbil Immediate Release (GE-IR) 450 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06097676
Gabapentin Enacarbil Immediate Release (GE-IR) 200 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06097676
Alprazolam 2 mg DRUG Phase PHASE4 Abuse Potential COMPLETED NCT06097676
Amphetamine Sulfate DRUG Phase PHASE3 Attention Deficit Hyperactivity Disorder COMPLETED NCT03659929
Azilsartan Medoxomil High-dose (40 mg) DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Azilsartan Medoxomil Medium-dose (20 mg) DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Placebo for Losartan DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Placebo for Azilsartan Medoxomil DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Losartan DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Azilsartan Medoxomil Low-dose DRUG Phase PHASE3 Hypertension COMPLETED NCT02235909
Carmustine 7.7Mg Wafer DRUG Phase PHASE2 Brain Tumor - Metastatic RECRUITING NCT04222062
Flunarizine DRUG Phase PHASE1 Pharmacokinetic Analysis NOT_YET_RECRUITING NCT07445464
1 mg epinephrine DRUG Phase PHASE2 Urticaria Chronic RECRUITING NCT06927999
0.5 mg epinephrine DRUG Phase PHASE2 Urticaria Chronic RECRUITING NCT06927999
Adrenaline DRUG Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Neffy DRUG Phase PHASE4 Allergic Reactions RECRUITING NCT06834165
Placebo DRUG Phase PHASE2 Vasomotor Symptoms (VMS) TERMINATED NCT02049164
Albuterol MDI DRUG Phase PHASE2 Asthma COMPLETED NCT05363670
ARS-1 DRUG Phase PHASE2 Urticaria COMPLETED NCT05496465
ARS-1 without URTI DRUG Phase PHASE1 Upper Respiratory Tract Infection COMPLETED NCT04930900
ARS-1 with URTI DRUG Phase PHASE1 Upper Respiratory Tract Infection COMPLETED NCT04930900
Total products: 96